Gilead expands its oncology pipeline
December 12 2012
Gilead's $510 million deal to buy YM Biosciences will bring an experimental bone marrow therapy under its roof.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.